Jᴏᴇ Wᴇɪ
@DrJoeWei
Followers
151
Following
1K
Media
22
Statuses
255
FRACP | PhD | Immunology | Oncology |
Joined June 2019
NSW government walks back claims of cancelled chemotherapy appointments during doctors' strike NSW doctor strike
9news.com.au
0
2
5
@DrJoeWei Topical given our chat today with @DouglasMataMD @FoundationATCG @Roche. Thanks for visiting @ScientiaAu and for the opportunity to learn from you and your team's impressive expertise! Hope you enjoy your time in Aus 🇦🇺☀️🌊⛱️🧬
🆕article on press: ctDNA detection in cerebrospinal fluid and plasma and mutational concordance with the primary tumor in a multicenter prospective study of patients with glioma @SantiCabezas1
https://t.co/30poE9pA1B
0
1
2
Medical director @CharlotteLemech represented @ScientiaAu at this supercharged meeting. Our oncologists are already getting excited by the @BioNTech_Group development pipeline! @DrJoeWei @DrChristinaTeng Looking forward to another fruitful collaboration in 2025.
Great to welcome the international team from BioNTech at TKCC today to meet with clinicians and researchers from Garvan/SVH and NECTA! It was a highly informative session learning about their latest trials and sharing our achievements in #earlyphasetrials #cancercare
0
1
4
🆕Article in press: Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy https://t.co/tzR3dljGYH
0
7
13
🚨 YOUNG ONC WORKSHOP IS HAPPENING THIS MORNING🚨 🙌🏻 Join @zarnielwin @DrMarkNalder @DrTimSlattery @BrandonBZLau for great sessions not be missed ⏰ 8am Perth 🕰️ 9am Brisbane ⏰ 10am Sydney & Melb @MOGA_ORG @drjameslynam
@AOParsonson @DrLizConnolly @nicolafoneil
1
7
17
Calling all Australian Medical Oncologists - what do you do when you are winning! How do you care for patients when immunotherapy WORKS? Share your knowledge and join us in a research project.
1
3
5
#AGITG24 was a stellar opportunity to catch up with some of the amazing clinicians who entrust me, @CharlotteLemech @DrJoeWei and the @ScientiaAu crew with their precious patients on #phase1oncology trials. As they say, #teamwork makes the dream work! 🤩🇦🇺🎯
What kinds of patients are referred for #phase1oncology trials at @ScientiaAu? @DrChristinaTeng presents #AGITG24 poster showing >50% patients with @GIcancer enrolled on trials come from outside metro Sydney. 👏 #babysteps for equity to trial access 📈
0
1
11
What kinds of patients are referred for #phase1oncology trials at @ScientiaAu? @DrChristinaTeng presents #AGITG24 poster showing >50% patients with @GIcancer enrolled on trials come from outside metro Sydney. 👏 #babysteps for equity to trial access 📈
0
1
7
Now do it to p53
🧬NTLA-2002 Gene Therapy Reduces Angioedema Attacks in Hereditary Angioedema 🧬🧬🧬 NTLA-2002 (25 mg or 50 mg) significantly reduces angioedema attacks by ~75% vs. placebo in hereditary angioedema patients. 🧬🧬🧬73% of patients on 50 mg were attack-free. Common side effects:
0
0
3
Looking for patients with #CIPN who have finished chemo to trial topical therapy⚡️🙌👣 @ScientiaAu Randwick, NSW. Pts can self refer or Dr/team can send thru their details. @ausyoungoncs @MOGA_ORG @COSA_Surviv @COSAoncology @GICancer @cancernetwork @PCPA_Ltd @CancerAustralia
If you have completed chemotherapy in past 3 to 15 months, and have CIPN as a result, then you might be able to participate in our new study. Contact our Recruitment Team on 1800 727 874, or email oxt328cipn@scientiaclinicalresearch.com.au, or message us directly here.
0
2
2
A thread worth going through! Thank you Dr @teachplaygrub
1/Do radiologists sound like they are speaking a different language when they talk about MRI? T1 shortening what? T2 prolongation who? Here’s a translation w/an introductory thread to MRI.
0
1
1
22yrs ago, where I first fell in love... ... ... ... ...in love with immunology 😭 #nostalgia #UniversityOfMelbourne #Immunology
0
0
6
Small interfering RNA incoming! Another technique we used to use to knock down genes in the lab... Looking forward to the day we CRISPR TP53 😂
The addition of siG12D LODER to SOC chemo generated responses and improved OS vs chemotherapy alone in patients with unresectable, locally advanced pancreatic cancer harboring KRASG12D/V mutations. #pancsm #oncology
https://t.co/p8vIQgkFPi
0
0
2
No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer. #bcsm #oncology
onclive.com
No significant improvement in OS was observed with Dato-DXd vs chemotherapy in pretreated HR-positive, HER2-low or -negative metastatic breast cancer.
0
1
4
An important study! Not all DCs are the same. At least in mice, DCs that can cross-prime activate tumour specific T cells. Using PBMCs derived DC for dendritic cell therapy may be suboptimal. #immunology
#ScienceSaturday Dendritic cells (DCs) play a critical role in activating CD4 and CD8 positive T cells to mediate the immune response against cancers. ❓But which DCs are the most important in triggering cancer-specific T cells? ➡️ In a recent report published in
0
0
4
We're excited to announce that COGNO is now on LinkedIn! Stay updated on our latest developments in clinical trials and connect with our team. Follow us here: https://t.co/J9FsOLdsAI
#ClinicalTrials #LinkedIn @COSAoncology
linkedin.com
COGNO - Cooperative Trials Group for Neuro-Oncology | 385 followers on LinkedIn. Achievement of better health outcomes for patients and those affected by brain tumours through clinical trials...
0
1
4
At @ScientiaAu we are running a trial using bispecific ADC targetting these 2 immune checkpoints expressed on tumour cells too! Excited about its outcomes! @DrChristinaTeng @CharlotteLemech
New #JITC article: Novel bispecific antibody-drug conjugate targeting PD-L1 and B7-H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses https://t.co/FZ9gAptwug
1
0
5
Amazing work. The more we understand the immune system, the better we can utilise it. The immune system is not only T cells. We need to learn to orchestrate the immune system better. NK cells, antigen presenting cells, B cells, chemokines, cytokines... We can, and will do better!
Here’s a deeper dive into #JITC article: “Spatial colocalization & combined survival benefit of NK & CD8 T cells despite profound MHC class I loss in NSCLC” from @sepiddsh @RemziyeErdogan5 @mgbvirginia1 @kategoundry20 at @UVABME @MedicineUVA @UVACancerCenter @UVAEngineers 1/11
0
0
2
"Sensing DNA as danger: The discovery of cGAS" by @FlavellLab and @esensefik discusses the importance of #LaskerAward winner Zhijian "James" Chen's work. @UTSWMedCenter @ImmunityCP
cell.com
Insight into how the immune system recognizes and responds to pathogens had led to landmark advances in biology and medicine in the last decades. This year’s Albert Lasker Award for Basic Medical...
1
23
88